Increased cardiovascular risk has been associated with reduced response to proerectile drugs.The Italian Society of Andrology andSexualMedicine (SIAMS) promoted an independent, multicenter study performed in 604 men (55 ± 12yrs) suffering from erectiledysfunction (ED) to assess multiple health outcomes and response to 6-month vardenafil challenge in a real-life setting. Overall,30.8% men had metabolic syndrome. Cardiovascular risk stratification revealed a greater number of ED subjects with moderaterisk of a major adverse cardiovascular event than the general population ( < 0.01). Age-adjusted pulse pressure was positivelycorrelated with ED severity and negatively with androgens and waist circumference ( < 0.01). A decline in total testosterone wasobserved with increasing arterial pulse pressure ( < 0.05), which was not accompanied by compensatory LH rise. Follow-up on185 men treated with vardenafil in an nonrandomized, open, single-arm trial documented a significant rise in IIEF-5 (delta =6.1 ±4.8) that was maintained in men with high cardiovascular risk. Mild adverse events occurred in <5%, with no differences betweencardiovascular risk classes. In summary, ED is a frequent symptom in patients with an elevated, but often unknown, risk of futurecardiovascular events. Androgens predict vascular resistance in ED patients. Vardenafil’s response and safety profile were preservedin subjects with higher cardiovascular risk.
The SIAMS-ED trial: a national, independetn, multicentre study on cardiometabolic and hormonal impairment of men with erectile dysfunction treated with vardenafil
CALOGERO, Aldo Eugenio;LA VIGNERA, SANDRO SALVUCCIO MARIA;
2014-01-01
Abstract
Increased cardiovascular risk has been associated with reduced response to proerectile drugs.The Italian Society of Andrology andSexualMedicine (SIAMS) promoted an independent, multicenter study performed in 604 men (55 ± 12yrs) suffering from erectiledysfunction (ED) to assess multiple health outcomes and response to 6-month vardenafil challenge in a real-life setting. Overall,30.8% men had metabolic syndrome. Cardiovascular risk stratification revealed a greater number of ED subjects with moderaterisk of a major adverse cardiovascular event than the general population ( < 0.01). Age-adjusted pulse pressure was positivelycorrelated with ED severity and negatively with androgens and waist circumference ( < 0.01). A decline in total testosterone wasobserved with increasing arterial pulse pressure ( < 0.05), which was not accompanied by compensatory LH rise. Follow-up on185 men treated with vardenafil in an nonrandomized, open, single-arm trial documented a significant rise in IIEF-5 (delta =6.1 ±4.8) that was maintained in men with high cardiovascular risk. Mild adverse events occurred in <5%, with no differences betweencardiovascular risk classes. In summary, ED is a frequent symptom in patients with an elevated, but often unknown, risk of futurecardiovascular events. Androgens predict vascular resistance in ED patients. Vardenafil’s response and safety profile were preservedin subjects with higher cardiovascular risk.File | Dimensione | Formato | |
---|---|---|---|
313_Isidori_IJE_2014.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Non specificato
Dimensione
1.55 MB
Formato
Adobe PDF
|
1.55 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.